Medicenna Therapeutics Corp.

11/27/2024 | Press release | Distributed by Public on 11/27/2024 06:20

Updated MDNA11 Monotherapy and Combination Clinical Data from the Ongoing Phase 1/2 ABILITY-1 Study to be Presented at the 2024 Immunotherapy Bridge Conference

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.